Fondaparinux sodium is a synthetic pentasaccharide anticoagulant supplied as a pharmaceutical-grade active pharmaceutical ingredient under the designation “Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable.” The product model is fondaparinux sodium, decasodium salt, cGMP injectable grade; the material is non-pyrogenic and is intended for verified formulation routes. The molecular structure is methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1→4)-O-β-D-glucopyranuronosyl-(1→4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1→4)-O-2-O-sulfo-α-L-idopyranuronosyl-(1→4)-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranoside, decasodium salt. The molecular formula is C31H43N3Na10O49S8, the relative molecular mass is 1728.08 g mol⁻¹, and the CAS registry number is 114870-03-0. The API is a white to slightly yellow hygroscopic powder bearing eight sulfate/sulfamate groups and ten sodium counterions. In plasma, fondaparinux sodium binds antithrombin III and selectively increases the rate of factor Xa inhibition by approximately 300-fold, without directly inhibiting thrombin. That selectivity distinguishes the product from unfractionated heparin and low-molecular-weight heparins. Because the molecule is highly anionic and displays low passive membrane permeability, the approved clinical route is subcutaneous injection; the oral and solid-dose designations in the product title represent development-grade material availability, not an approved oral indication.

What Limits Oral Bioavailability in a Pentasaccharide Anticoagulant API?

Oral absorption of fondaparinux sodium is constrained by the octasulfated oligosaccharide architecture. The molecular mass of 1728.08 g mol⁻¹, the negative charge from ten sodium-associated sulfate/sulfamate sites, and the absence of neutral hydrophobic regions restrict diffusion across the lipid bilayer of the jejunum and ileum. The calculated octanol-water partition coefficient is strongly negative; paracellular transport is limited by the hydrodynamic radius of the molecule. The oral presentation in the API designation therefore requires interpretation as a research-grade or formulation-development category. Published human oral bioavailability data are limited; regulatory approval is based on subcutaneous pharmacokinetics, where absorption is essentially complete and dose-proportional over the labeled range. The elimination half-life in adults with normal renal function is approximately 17 h, which supports once-daily subcutaneous dosing. Enteric-coated, permeability-enhanced, or nanoparticle-based oral systems have not been established in compendial monographs or approved product labeling.

In injectable manufacturing, the high aqueous solubility of fondaparinux sodium is attributed to the ionized sulfate groups. Compounding in a jacketed stainless-steel vessel at 2–8 °C slows the acid-catalyzed desulfation that can occur in aqueous solution under thermal stress. The solution is passed through a 0.22 µm sterilizing-grade filter and filled aseptically; terminal steam sterilization is avoided because the sulfate ester linkages are susceptible to hydrolysis at autoclave temperatures. pH is monitored, and excursions are controlled to the registered specification range. A typical parenteral formulation contains fondaparinux sodium at 2.5 mg per 0.5 mL or comparable prefilled-syringe presentations, based on approved labeling. Subvisible particulates are controlled by light obscuration per USP <788>, and clarity is confirmed against compendial reference suspensions. For lyophilized presentations, the API solution is freeze-dried in stainless-steel trays; cycle parameters are selected to avoid collapse above the glass transition temperature, and the dried cake is backfilled with nitrogen to limit moisture uptake. Residual moisture is measured by Karl Fischer titration according to USP <921>.

Sulfate Ester Hydrolysis and Aseptic Processing Boundaries

Hydrolytic degradation of fondaparinux sodium generates free sulfate and desulfated oligosaccharide species that are quantified by anion-exchange high-performance liquid chromatography. The rate of degradation is pH- and temperature-dependent; low pH increases the susceptibility of the sulfamate groups to hydrolysis, while high pH can promote alkali-mediated elimination at the reducing or oxidized termini. Drug-substance release therefore includes a chromatographic purity test that separates the intact pentasaccharide from structural impurities and process-related sulfate-bearing fragments. Residual solvents are controlled according to ICH Q3C, with gas chromatography using procedures aligned to USP <467>. Elemental impurities are assessed according to ICH Q3D, typically using inductively coupled plasma mass spectrometry or optical emission spectroscopy following acid digestion, as described in USP <232>/<233>. The bacterial endotoxin limit for injectable API is assigned from the maximum adult human dose using the formula K/M, where K is 5 EU/kg for parenteral products and M is the maximum dose in mg/kg; a typical release limit is therefore lower than 0.10 EU/mg, but the registered limit may differ. Microbiological quality is evaluated by total aerobic microbial count, total combined yeast and mold count, and specified organisms per USP <61>/<62>.

Batch-to-batch control of fondaparinux sodium differs fundamentally from animal-sourced heparins because the starting materials and chemical synthesis are defined. Release testing includes specific optical rotation, infrared absorption against a reference standard, sodium content, chloride content, related carbohydrate impurities, free sulfate, and residual solvents. High-performance liquid chromatography with ultraviolet or charged aerosol detection resolves the parent pentasaccharide from process intermediates. The consistency of the heterogeneous impurity profile is narrower than that of low-molecular-weight heparin APIs, where natural feedstock variation requires multiple orthogonal activity assays. However, fondaparinux sodium is cleared predominantly by renal elimination, and accumulation occurs when creatinine clearance declines below 30 mL/min; this limits application in severe renal impairment unless labeled otherwise. There is no established oral solid-dosage monograph, and published data for this specific configuration is limited.

When Granulation of an Ionic Pentasaccharide Encounters Humidity and Static Charge

Although the marketing category includes tablet, capsule, and granule presentation, the established use of fondaparinux sodium is injectable. Dry processing of the bulk powder is complicated by hygroscopicity, electrostatic charging, and adhesive behavior on metal contact surfaces. Roller compaction on a pilot-scale compactor with 100 mm rolls typically requires process-air dew point below -20 °C and relative humidity below 30% to control sticking and picking. Wet granulation introduces aqueous shear and drying heat that may accelerate desulfation of the sulfate ester bonds, reducing chromatographic purity. If an immediate-release capsule is evaluated, the API must be blended in a low-shear tumble blender at slow speed to minimize triboelectric charging; high-shear high-speed mixing may produce cohesive agglomerates that segregate during transfer. Published data for this specific configuration is limited. The product is therefore not interchangeable with oral anticoagulant APIs, whose absorption occurs via conventional gastrointestinal permeability mechanisms.

The representative release specification for fondaparinux sodium is summarized in the following compliance table. Exact registered values may differ by regulatory dossier and intended route.

Platelet Factor 4 Binding and the Short Pentasaccharide Chain

Differences from heparin-based products are determined by chain length and sulfation pattern. Fondaparinux sodium forms a binary antithrombin III–fondaparinux complex, whereas unfractionated heparin forms an antithrombin III–heparin–thrombin ternary complex. The pentasaccharide length is sufficient for antithrombin III-mediated factor Xa inhibition but too short for simultaneous binding of platelet factor 4; this reduces the likelihood of the PF4–heparin complex that drives heparin-induced thrombocytopenia. Enoxaparin sodium occupies an intermediate position, with shorter chains than unfractionated heparin but longer than fondaparinux sodium. The low-molecular-weight heparin APIs retain some PF4 interaction and varying ability to inhibit factor IIa. In contrast, fondaparinux sodium does not directly inhibit thrombin and is not neutralized by protamine sulfate. This absence of reversal should be considered during invasive procedures and patients with bleeding risk. The product should not be combined with other anticoagulants outside labeled protocols, and contraindications for active bleeding or thrombocytopenia should be followed.

Unlike oral direct factor Xa inhibitors such as rivaroxaban, apixaban, and edoxaban, fondaparinux sodium is not orally bioavailable and requires subcutaneous injection. Direct oral factor Xa inhibitors have molecular masses below 600 g mol⁻¹ and inhibit factor Xa directly without antithrombin III; fondaparinux sodium has a molecular mass of 1728.08 g mol⁻¹ and requires antithrombin III for activity. This mechanistic difference alters reversal options, monitoring considerations, and hepatic versus renal elimination profiles. Labeled uses of fondaparinux sodium include prophylaxis of deep vein thrombosis in patients undergoing hip fracture, hip replacement, or knee replacement surgery, and treatment of acute deep vein thrombosis and pulmonary embolism when administered with warfarin. The API is not indicated for intramuscular injection.

In terms of storage, the bulk API is hygroscopic and requires closed-container storage at controlled room temperature, normally 20–25 °C, with desiccant protection when relative humidity exceeds 60%. Containers should be opened under nitrogen where feasible; repeated ambient exposure can increase surface moisture and reduce the precision of charge-weight dispensing. The API is unsuitable for direct blending in open planetary mixers without environmental controls. For injectable solution preparation, the liquid intermediate should be used within the validated hold time, and bioburden should be measured before filtration. Freeze-thaw cycles of bulk solution are not recommended unless specifically validated, because polysaccharide aggregation and subvisible particle formation may occur.